Timing matters: study tests if starting gout drug during a flare is safe
NCT ID NCT07661030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares starting dotinurad, a urate-lowering drug, during an acute gout flare versus waiting until the flare resolves. About 142 adults with gout will be randomly assigned to one of two timing schedules. Researchers will measure how quickly the flare resolves and whether starting early increases pain or inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dotinurad
- What this could lead to
- If successful, this could show that starting urate-lowering therapy during a gout flare is safe and does not worsen pain or inflammation, allowing earlier treatment.
- What could go wrong
- This is a phase 4 trial with a moderate number of participants. It may not prove long-term benefits, and some patients might experience increased pain or flare recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection tame Gout's uric acid?
- Can an ancient herbal formula tame gout?
- New drug combo aims to tame stubborn gout flares
- Ultrasound may solve arthritis diagnosis puzzle
- Probiotic supplement shows promise for gout prevention in small study
- New gout drug dotinurad shows promise in early trial